FDA Launches Long-Awaited Medical Device Surveillance System

The FDA is finally launching a long-awaited surveillance system to monitor medical device safety, 12 years after it was mandated. This system will utilize real-world evidence (RWE) from electronic health records and billing claims to identify safety issues in near real-time.

Currently, the FDA relies on inconsistent reports from manufacturers and healthcare providers, leading to underreporting of harmful devices like surgical meshes and CPAP machines.

Despite this initiative, experts remain skeptical about its effectiveness. The FDA plans to start monitoring just two device types this year, with a slow expansion to 18 devices by 2028, which is a small fraction of the over 6,000 devices it regulates. Challenges such as inadequate funding, limited use of unique device identifiers, and lax testing standards for new devices further complicate the situation.

Critics emphasize that improved surveillance doesn’t address fundamental issues in device approval processes and urge journalists to scrutinize the FDA’s efforts. They suggest asking questions about data-sharing partnerships, the impact of patient mobility on reporting, and the need for mandatory tracking of high-risk devices.

Overall, while the new system marks a step forward, many believe it falls short of what is needed to ensure medical device safety.

Read the full article here

We frequently leverage decades of direct industry knowledge and deep relationships to source targets at lower multiples before they come to market. These tend to be micro-cap companies in fragmented markets that are in the early stages of consolidation and which will benefit from transformative trends.  To explore investing in healthcare with our private equity team, contact us at info@grantchestergrowth.com.